MON-645 Association of Baseline Cardio-Metabolic Parameters on the Treatment Effects of Empagliflozin When Added to Metformin in Patients with T2D

Sodium-glucose co-transporter-2 inhibitors (SGLT2i) are commonly used as 2(nd)-line therapy after metformin (MET) in patients with type 2 diabetes (T2D), and are now recommended in those with co-existing cardiovascular (CV) and/or chronic kidney disease (CKD). A better understanding of their clinica...

Descripción completa

Detalles Bibliográficos
Autores principales: Inzucchi, Silvio E, Davies, Melanie, Khunti, Kamlesh, Trivedi, Prabhav, George, Jyothis T, Zwiener, Isabella, Johansen, Odd Erik, Sattar, Naveed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Diabetes Mellitus and Glucose Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209010/
http://dx.doi.org/10.1210/jendso/bvaa046.414

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209010/
http://dx.doi.org/10.1210/jendso/bvaa046.414

Ejemplares similares